Journal Mobile Options
Table of Contents
Vol. 55, No. 3-4, 2007
Issue release date: October 2007
Neuropsychobiology 2007;55:176–183
(DOI:10.1159/000107070)

Psychotropic Profile of S 17092, a Prolyl Endopeptidase Inhibitor, Using Quantitative EEG in Young Healthy Volunteers

Morain P. · Boeijinga P.H. · Demazières A. · De Nanteuil G. · Luthringer R.
aIRIS, Institut de Recherches Internationales SERVIER, Courbevoie, and bFORENAP, Research Institute for Neuroscience, Pharmacology and Psychiatry, Rouffach, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The central activity of S 17092, a prolyl endopeptidase (PEP) inhibitor, was investigated by quantitative electroencephalography (qEEG) in 48 young healthy men participating in a double-blind, randomized, placebo-controlled, cross-over study. S 17092 (100, 200, 400 or 600 mg) and placebo were administered once daily for 10 days in a rising multiple-dose scheme. EEG recordings were performed before and repeatedly from 0.5 to 24 h after dose on day 1 and day 10. PEP activity in plasma was also measured for the same periods. S 17092 appeared as a potent inhibitor of PEP activity at all doses, after both single and repeated administrations. EEG changes after acute doses were slight and of short duration, mainly characterized by increased relative alpha 1 power, suggesting a vigilance-promoting EEG profile. After repeated doses and more strikingly after a superimposed dose, increases in relative alpha 1 power were still present with additional increase in relative delta power and decreases in absolute fast alpha, fast beta, theta powers and total power at all doses. These EEG findings suggest that S 17092 might possess some mood-stabilizing potential in addition to its cognition-enhancing properties.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Barelli H, Petit A, Hirsch E, Wilk S, De Nanteuil G, Morain P, Checler F: S 17092–1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. Biochem Biophys Res Commun 1999;257:657–661.
  2. Bellemere G, Morain P, Vaudry H, Jegou S: Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem 2003;84:919–929.
  3. Bellemere G, Vaudry H, Morain P, Jegou S: Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophin-releasing hormone catabolism in the rat brain. J Neuroendocrinol 2005;17:306–313.
  4. Marighetto A, Touzani K, Etchamendy N, Torrea CC, De Nanteuil G, Guez D, et al: Further evidence for a dissociation between different forms of mnemonic expressions in a mouse model of age-related cognitive decline: effects of tacrine and S 17092, a novel prolyl endopeptidase inhibitor. Learn Mem 2000;7:159–169.
  5. Morain P, Lestage P, De Nanteuil G, Jochemsen R, Robin JL, Guez D, et al: S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment – Preclinical and clinical studies. CNS Drug Rev 2002;8:31–52.
  6. Schneider JS, Giardiniere M, Morain P: Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys. Neuropsychopharmacology 2002;26:176–182.
  7. Morain P, Robin JL, De Nanteuil G, Jochemsen R, Heidet V, Guez D: Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers: a phase I study. Br J Clin Pharmacol 2000;50:350–359.
  8. Maes M, Goossens F, Scharpe S, Meltzer HY, D’Hondt P, Cosyns P: Lower serum prolyl endopeptidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression. Biol Psychiatry 1994;35:545–552.
  9. Maes M, Goossens F, Scharpé S, Calabrese J, Desnyder R, Meltzer HY: Alterations in plasma propyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res 1995;58:217–225.
  10. Maes M, Goossens F, Lin A, De Meester I, Van Gastel A, Scharpe S: Effects of psychological stress on serum prolyl endopeptidase and dipeptidyl peptidase IV activity in humans: higher serum prolyl endopeptidase activity is related to stress-induced anxiety. Psychoneuroendocrinology 1998;23:485–495.
  11. Williams RS, Eames M, Ryves WJ, Viggars J, Harwood AJ: Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate. EMBO J 1999;18:2734–2745.
  12. Williams RS, Harwood AJ: Lithium therapy and signal transduction. Trends Pharmacol Sci 2000;21:61–64.
  13. Harwood AJ, Agam G: Search for a common mechanism of mood stabilizers. Biochem Pharmacol 2003;66:179–189.
  14. Cheng L, Lumb M, Polgar L, Mudge WA: How can the mood stabilizer VPA limit both mania and depression? Mol Cell Neurosci 2005;29:155–161.
  15. Saletu B: Pharmacodynamics and EEG: advances in pharmaco-EEG; in Krijzer F, Hermann WM (eds): Practical and Theoretical Considerations in Preclinical and Clinical Studies. Berlin, Zentrale Universitätsdruckerei 1996, pp 187–204.
  16. Saletu B: Pharmaco-EEG profiles of typical and atypical antidepressants; in E Costa, G Racagni (eds): Typical and Atypical Antidepressants. Clinical Practice. New York, Raven Press, pp 257–268.
  17. Herrmann WM: Development and critical evaluation of an objective procedure for the electroencephalographic classification of psychotropic drugs; in Herrmann WM (ed): Electroencephalography in Drug Research. Stuttgart, Fischer, 1982, pp 249–352.
  18. Goossens F, De Meester I, Wanhoof G, Scharpé S: A sensitive method for the assay of serum propyl endopeptidase. Eur J Clin Chem Clin Biochem 1992;30:235–238.
  19. Dago KT, Luthringer R, Lengellé R, Rinaudo G, Macher JP: Statistical decision tree: a tool for studying pharmaco-EEG effects of CNS-active drugs. Neuropsychobiology 1994;29:91–96.
  20. Itil TM, Eralp E, Tsambis E, Itil KZ, Stein U: Central nervous system effects of Ginkgo biloba, a plant extract. Am J Ther 1996;3:63–73.
  21. Luthringer R, d’Ardigny P, Macher JP: Ginkgo biloba extract (Egb 761), EEG and event-related potentials mapping profile; in Christen Y, Courtois Y, Droy-Lefaix M-T (eds): Advances in Ginkgo biloba Extract Research. 4. Effects of Ginkgo biloba Extract (Egb 761) on Aging and Age-Related Disorders. Paris, Elsevier, 1995, pp 107–118.
  22. Saletu B, Anderer P, Di Padova C, Assandri A, Saletu-Zyhlarz GM: Electrophysiological neuroimaging of the central effects of S-adenosyl-L-methionine by mapping of electroencephalograms and event-related potentials and low-resolution brain electromagnetic tomography. Am J Clin Nutr 2002;76:1162S–1171S.
  23. Saletu B, Grünberger J, Linzmayer L: Is amezinium metilsulfate – a new antihypotensive drug – psychoactive? Comparative quantitative EEG and psychometric trials with desipramine and methamphetamine. Curr Ther Res 1980;28:800–826.
  24. Luthringer R, Dago KT, Patat A, Caille P, Curet O, Durieu G, Rinaudo G, Toussaint M, Granier LA, Macher JP: Pharmacoelectroencephalographic profile of befloxatone, a new reversible MAO-A inhibitor, in healthy subjects. Neuropsychobiology 1996;34:98–105.
  25. Herrmann WM, Fuder H: Reboxetine, a selective noradrenaline reuptake inhibitor, is non-sedative and does not impair psychomotor performance in healthy subjects. Hum Psychopharmacol 1998;13:425–433.
  26. Saletu B, Grünberger J: Classification and determination of cerebral bioavailability of fluoxetine: pharmacokinetic, pharmaco-EEG, and psychometric analyses. J Clin Psychiatry 1985;46:45–52.
  27. Saletu B, Grünberger J: Early clinical pharmacological trials with a new antiepileptic, milacemide, using pharmaco-EEG and psychometry. Methods Find Exp Clin Pharmacol 1984;6:317–330.
  28. Schulz I, Gerhartz B, Neubauer A, Holloschi A, Heiser U, Hafner M, Demuth MU: Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. Eur J Biochem 2002;269:5813–5820.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50